Developing and Nationalizing Key Cannabis Research Act of 2022
USA117th CongressHR-8540| House
| Updated: 11/1/2022
Scott H. Peters
Democratic Representative
California
Cosponsors (1)
Crime and Federal Government Surveillance Subcommittee, Judiciary Committee, Energy and Commerce Committee
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Developing and Nationalizing Key Cannabis Research Act of 2022 This bill directs the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) to expand activities concerning cannabis research. The NIH must collaborate with specified agencies to develop a national cannabis research agenda. Among other topics, the agenda must address (1) the therapeutic benefits of cannabis, (2) how cannabis effects specified populations, and (3) other public safety considerations. Additionally, the NIH must designate centers of excellence in cannabis research at institutions of higher education to conduct interdisciplinary research about biomedical, behavioral, and social issues related to cannabis. The CDC must work with other agencies to collect population-wide data about cannabis use, including (1) demographic factors, (2) health outcomes, (3) product variety, and (4) other relevant health information.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Subcommittee on Crime, Terrorism, and Homeland Security.
Health
Developing and Nationalizing Key Cannabis Research Act of 2022
USA117th CongressHR-8540| House
| Updated: 11/1/2022
Developing and Nationalizing Key Cannabis Research Act of 2022 This bill directs the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) to expand activities concerning cannabis research. The NIH must collaborate with specified agencies to develop a national cannabis research agenda. Among other topics, the agenda must address (1) the therapeutic benefits of cannabis, (2) how cannabis effects specified populations, and (3) other public safety considerations. Additionally, the NIH must designate centers of excellence in cannabis research at institutions of higher education to conduct interdisciplinary research about biomedical, behavioral, and social issues related to cannabis. The CDC must work with other agencies to collect population-wide data about cannabis use, including (1) demographic factors, (2) health outcomes, (3) product variety, and (4) other relevant health information.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Subcommittee on Crime, Terrorism, and Homeland Security.
Scott H. Peters
Democratic Representative
California
Cosponsors (1)
Crime and Federal Government Surveillance Subcommittee, Judiciary Committee, Energy and Commerce Committee
Health
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted